10-Q: Encision Reports Q1 Loss Amid Product Revenue Decline

Encision Inc. reported a net loss of $41,133 for the quarter ended June 30, 2025, primarily driven by a 6% decrease in product revenue.

Summary

• Reported a net loss of $41,133 for the three months ended June 30, 2025, compared to a net income of $22,041 for the same period in 2024.
• Total revenue decreased to $1,602,728 in Q1 2025 from $1,630,931 in Q1 2024.
• Product revenue declined by 6% to $1,492,832 in Q1 2025, down from $1,591,960 in Q1 2024, primarily due to reduced sales of disposable products and lower procedural volume.
• Service revenue significantly increased to $109,896 in Q1 2025 from $38,971 in Q1 2024, mainly due to services performed under a Master Services Agreement with Vicarious Surgical Inc.
• Gross profit decreased by 7% to $878,459 in Q1 2025 from $942,663 in Q1 2024, with product gross margin falling from 58% to 55%.
• Operating results shifted from an income of $28,343 in Q1 2024 to a loss of $19,780 in Q1 2025.
• Cash balance decreased by $209,515 to $47,918 at June 30, 2025, from $257,433 at March 31, 2025.
• Net cash used in operating activities was $115,508 for the quarter, a reversal from $117,528 provided in the prior year.
• Working capital increased by $135,816 to $1,172,666 at June 30, 2025.
• Accumulated deficit grew to $22,806,378 at June 30, 2025.
• Internal control over financial reporting was deemed not effective as of June 30, 2025, due to inadequate segregation of duties, with remediation efforts ongoing.

Sentiment

Score: 3

Explanation: The company reported a net loss, declining product revenue, negative operating cash flow, and a reduced cash balance. While service revenue saw strong growth and management is taking steps to improve operations and liquidity, the overall financial performance for the quarter was negative, and internal control weaknesses persist, indicating significant challenges.

Positives

• Service revenue saw a substantial increase of 182% to $109,896, driven by a strategic partnership with Vicarious Surgical Inc.
• Working capital improved by $135,816, reaching $1,172,666 at June 30, 2025.
• Management is actively developing plans to ensure sufficient working capital for the next twelve months.
• Product pricing was increased to mitigate the impact of higher material costs.
• Sales and marketing expenses decreased by 4% to $404,601, primarily due to reduced sales commissions.
• General and administrative expenses decreased by 7% to $328,198, attributed to reductions in contract services and regulatory expenses.
• Holds 26 unexpired relevant patents, establishing a significant intellectual property position in AEM technology.
• Committed to improving and expanding AEM technology penetration and developing next-generation products.
• Exploring overseas markets and opportunities for licensing arrangements and strategic alliances to further market reach.

Negatives

• Reported a net loss of $41,133 for the quarter, a significant decline from a net income of $22,041 in the prior year.
• Product revenue decreased by 6% to $1,492,832, indicating a reduction in sales volume, particularly for disposable products.
• Total revenue experienced a slight decrease of 1.7% year-over-year.
• Gross profit decreased by 7% to $878,459, and the gross margin on product net revenue declined from 58% to 55%.
• Operating results shifted from an income to a loss, reflecting operational challenges.
• Cash balance significantly decreased by $209,515, ending the quarter with only $47,918.
• Net cash used in operating activities was $115,508, a negative shift from cash provided in the previous year.
• The accumulated deficit increased to $22,806,378, highlighting ongoing historical losses.
• Internal control over financial reporting was determined to be not effective due to inadequate segregation of duties, posing a material weakness.
• Interest expense, net, increased to $18,009 from $6,369 in the prior year.

Risks

• Future operating losses could diminish liquidity, potentially requiring the company to seek additional capital.
• Actual market conditions being less favorable than management's projections may necessitate additional inventory write-downs.
• Exposure to credit risk associated with the healthcare industry due to unsecured accounts receivable.
• The possibility of operating at a net loss due to the ongoing need to develop, optimize, and train the sales network, support product line refinements, and increase sales to cover costs.
• Sustained losses or inability to generate sufficient cash flow from operations could lead to a need for additional capital.
• Acceptance of AEM products depends on surgeons' preferences for instruments, and if other instruments are preferred, business results will suffer.
• Omission or delay of elective surgeries would negatively impact the extent and timing of revenue growth.
• Longer-term initiatives such as developing next-generation products, entering international markets, or forming strategic partnerships may not materialize or be successfully capitalized upon.
• Inability to manage business operations in line with budget expectations could materially adversely affect business viability, financial position, results of operations, and cash flows.
• Net operating loss carryforwards may be limited by tax regulations if certain events, such as changes in ownership interests, occur.
• Estimates used in financial statements (e.g., bad debts, inventories, warranties) may differ from actual results, requiring revisions.
• The carrying value of patents is reviewed periodically, and future assessments could result in impairment charges against earnings.
• Internal control over financial reporting was not effective as of June 30, 2025, due to inadequate segregation of duties, which is reasonably likely to adversely affect the ability to record, process, summarize, and report financial information.

Future Outlook

Management expects sales of AEM products to increase as the inherent risks associated with monopolar laparoscopic electrosurgery become more widely acknowledged and as sales efficiency improves. Replacement sales of electrosurgical instruments and accessories are also anticipated to grow as additional facilities adopt AEM technology. The company aims to optimize sales execution, expand market awareness of AEM technology, and maximize the number of additional hospital and surgery center accounts switching to AEM instruments while retaining existing customers in fiscal year 2026. Research and development expenses are expected to increase to support product line refinements and new product development. The company is exploring overseas markets and opportunities for licensing arrangements and strategic alliances, though these are longer-term initiatives with uncertain outcomes and may not materialize.

Management Comments

• "The Company believes that the patent AEM (Active Electrode Monitoring) surgical instrument technology is changing the marketplace for electrosurgical devices and instruments by providing a solution to a patient safety risk in laparoscopic surgery."
• "Management concludes that it is probable that cash resources and line of credit will be sufficient to meet cash requirements for twelve months from the issuance of the unaudited condensed financial statements."
• "We believe that our patented Active Electrode Monitoring (AEM) AEM EndoShield Burn Protection System is changing the marketplace for electrosurgical devices and laparoscopic instruments by providing a solution to a well-documented hazard unique to laparoscopic surgery."
• "We believe that there is no directly competing technology to supplant AEM products."
• "We believe that the unique performance of the AEM technology and our breadth of independent endorsements provide an opportunity for continued market share growth."
• "In our view, market awareness and awareness of the clinical credibility of the AEM technology, as well as awareness of our endorsements, are improving, and we expect this awareness to benefit our sales efforts for the remainder of the fiscal year 2026."
• "Our objectives for the remainder of fiscal year 2026 are to optimize sales execution, expand market awareness of the AEM technology, and maximize the number of additional hospital and surgery center accounts switching to AEM instruments while retaining existing customers."
• "We expect to generate increased product revenue in the U.S. from sales to new customers and from expanded sales to existing customers as the medical device industry stabilizes and our network of direct and independent sales representatives becomes more efficient."
• "We expect that the development of next-generation versions of our AEM products will better position our products in the marketplace and improve our retention rate at hospitals and surgery centers that have changed to AEM technology, enabling us to grow our sales."

Industry Context

The company operates in the medical device industry, specifically focusing on minimally invasive surgery (MIS) and electrosurgery devices. The market opportunity is driven by the increasing use of MIS and the documented risks of unintended electrosurgical burn injuries, which the company's AEM technology aims to mitigate. The Center for Medicare and Medicaid Services' Hospital-Acquired Condition Reduction Program, which levies penalties for accidental puncture and laceration (APL), creates a regulatory incentive for hospitals to adopt safer technologies like AEM. The company's strategy aligns with the industry trend towards enhanced patient safety and risk reduction in surgical procedures.

Comparison to Industry Standards

• The filing does not provide specific comparable company or project data to assess results against global benchmarks.
• The company highlights that its AEM technology addresses a well-documented hazard in laparoscopic surgery, a risk that conventional monopolar electrosurgery instruments are susceptible to, positioning its products as a safety enhancement.
• AEM Surgical Instruments are claimed to be equivalent to conventional instruments in size, shape, ergonomics, functionality, and competitive pricing, while offering the added benefit of enhanced patient safety.
• AEM technology has received recommendations and endorsements from various groups involved in MIS, including surgeons, nurses, biomedical engineers, and malpractice insurance carriers, suggesting a positive reception and perceived advantage within the medical community regarding its safety benefits compared to standard practices.

Corporate Governance

Stakeholder Impact

• Shareholders experienced a net loss and a decrease in total shareholders' equity, potentially impacting share value. The explicit risk of needing to raise additional capital if operating losses continue could lead to dilution.
• Customers (Hospitals/Surgery Centers) are targeted with efforts to expand AEM technology penetration and develop next-generation products, aiming to provide enhanced patient safety and improved instrument options.
• Employees had stock-based compensation expense recognized. Remediation efforts for internal controls might affect financial reporting responsibilities.
• Creditors, including lenders for the EIDL, U.S. Bank loans, and the Pathward line of credit, as well as lessors, face potential concerns due to the decrease in cash and operating loss, though management believes cash resources and the line of credit will be sufficient for 12 months.

Next Steps

• Optimize sales execution and expand market awareness of AEM technology.
• Maximize the number of additional hospital and surgery center accounts switching to AEM instruments while retaining existing customers.
• Develop next-generation versions of AEM products to enhance market positioning and customer retention.
• Explore overseas markets to assess opportunities for international sales growth.
• Explore opportunities to capitalize on AEM technology via licensing arrangements and strategic alliances.
• Continue remediation efforts for internal control over financial reporting, including evaluating additional review and approval processes, expanding documentation, restructuring financial reporting responsibilities, and potentially hiring external consultants.

Key Dates

Recommendation

The company reported a net loss, a 6% decline in product revenue, and a significant reduction in cash from operations, indicating deteriorating financial performance. The gross margin also decreased. While service revenue grew, it did not offset the product revenue decline. Furthermore, the company acknowledged a material weakness in internal control over financial reporting due to inadequate segregation of duties, which is a serious governance concern. The accumulated deficit continues to grow, and there's an explicit risk of needing to raise additional capital if operating losses persist, which could dilute existing shareholders. These factors collectively point to significant operational and financial challenges, making the stock a 'sell' for a seasoned investor.

Keywords

Medical device, Surgical instruments, AEM technology, Active Electrode Monitoring, Laparoscopic surgery, Patient safety, Electrosurgery, Healthcare, Financial reporting, 10-Q, Encision Inc., ECIA